Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· May 15, 2026

Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu

Aktionärinnen und Aktionäre der BioNTech SE stimmen auf der ordentlichen Hauptversammlung 2026 allen Tagesordnungspunkten zu MAINZ, Deutschland, 15…

Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

BioNTech is intensifying its focus on its growing late-stage oncology pipeline while continuing early research and development aimed at long-term innovations.
60% confidence
Forward-looking statements in this press release are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
60% confidence
BioNTech aims to sustainably improve treatment options for people with cancer and develop innovative drugs with tumor-cross-cutting or synergistic potential to address cancer across all stages of the disease.
60% confidence
Readers are advised to review Risk Factors in BioNTech's Form 6-K report for the period ending March 31, 2026, and subsequent SEC filings.
60% confidence

BioNTech SE · supervisory board size	8 members
BioNTech SE · shareholder attendance	92 percent